Strategic Partnerships Ensysce Biosciences Inc. has recently partnered with Purisys LLC to advance its opioid use disorder (OUD) drug candidate, presenting a potential sales opportunity for collaboration on drug development endeavors.
Funding Success With recent financing such as the $5 million secured from stock sales and a $14 million grant from the National Institutes of Health, Ensysce Biosciences is financially bolstered, potentially signifying an increased capacity for investment in products or services.
Government Grants Receiving a $14 million multi-year grant from the NIH and National Institute on Drug Abuse showcases governmental support for Ensysce Biosciences' drug development projects, hinting at potential future sales collaborations or partnerships.
Industry Recognition The FDA's designation of Ensysce Biosciences' abuse-deterrent opioid as a Breakthrough Therapy in 2024 demonstrates industry validation, potentially opening doors for sales discussions and partnerships with regulatory authorities or pharmaceutical companies.
Conference Presence Ensysce Biosciences' participation in events like the PAINWeek 2023 Symposium indicates an active engagement within the industry, offering opportunities for networking, showcasing products, and potential sales leads or partnerships stemming from such conferences.
Ensysce Biosciences uses 8 technology products and services including MySQL, Google Font API, jQuery, and more. Explore Ensysce Biosciences's tech stack below.
| Ensysce Biosciences Email Formats | Percentage |
| FLast@ensysce.com | 50% |
| FLast@ensysce.com | 50% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.
Company Overview
Media & News
Funding & FinancialsEnsysce Biosciences has raised a total of $15M of funding over 9 rounds. Their latest funding round was raised on Jun 06, 2024 in the amount of $15M.
Funding & FinancialsEnsysce Biosciences has raised a total of $15M of funding over 9 rounds. Their latest funding round was raised on Jun 06, 2024 in the amount of $15M.
1-888-653-2347 
support@leadiq.com